SequelSEC

Mineralys Therapeutics, Inc. MLYS

Pharmaceutical Preparations · CIK 0001933414 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$170.60M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Mineralys Therapeutics, Inc. (MLYS) reported net income of -$154.65M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Mineralys Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Mineralys Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$170.60M-$192.40M-$84.66M-$31.48M
Net income-$154.65M-$177.81M-$71.90M-$29.80M
Research & development$132.01M$168.58M$70.36M$26.25M
Weighted-average diluted sharesshares 67.66Mshares 48.54Mshares 36.19Mshares 5.17M
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailableUnavailable
Diluted EPS$-2.29$-3.66$-1.99$-5.77
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$38.60M$23.82M$14.30M$5.23M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Mineralys Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$172.92M$114.09M$49.30M$87.70M
Total assets$661.81M$205.90M$251.64M$114.44M
Current assets$661.39M$205.35M$249.10M$112.81M
Total liabilities$15.11MUnavailableUnavailableUnavailable
Current liabilities$15.11M$14.65M$10.48M$8.07M
Total equity incl. NCI$646.69M$191.26M$241.15M-$52.27M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.02M$479.00K$601.00K$1.91M

Cash flow

Mineralys Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$142.42M-$166.31M-$81.17M-$29.22M
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$389.75M$114.96M-$160.47M-$21.76M
Financing cash flow$591.00M$116.14M$203.25M$128.02M
Net change in cash$58.83M$64.79M-$38.40M$77.04M
Stock-based compensation$19.32M$11.34M$5.06M$455.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$59.00K$43.00K$0Unavailable

Derived

Mineralys Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio43.76x14.02x23.76x13.98x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MLYS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.